%0 Journal Article
%T 伴FLT3突变的AML的治疗进展<br>Progress in the Treatment of AML with FLT3 Mutation
%A 何君
%A 罗伟
%J Advances in Clinical Medicine
%P 8254-8260
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.1351155
%X 急性髓系白血病(AML)是一种来源于造血干细胞或祖细胞的恶性克隆性、增殖性疾病，致残率和致死率极高。大约30%的AML病人存在FLT3基因的突变，其中ITD是最主要的一种。FLT3-ITD基因突变可导致白细胞增多，且预后差。AML的治疗近年来取得较大进展，靶向治疗与高强度的化学药物结合，是一种有效挽救性治疗方法，并且可作为同种异体移植的桥梁。现简要综述伴FLT3突变的AML的治疗进展。<br />
Acute myeloid leukemia (AML) is a malignant clonal and proliferative disease derived from hema-topoietic stem cells or progenitor cells, with high morbidity and mortality. About 30% of AML pa-tients develop mutations in the FLT3 gene, and ITD mutations are one of the most common types of FLT3 mutations. Patients with the FLT3-ITD mutation have high leukocyte expression and a poor prognosis. The treatment of acute myeloid leukemia (AML) has made great progress in recent years. Targeted therapy combined with intense chemotherapy is a viable option for salvage treatment of AML and can serve as a bridge to allotransplantation. This article reviews the progress in the treatment of AML with FLT3 mutations.
%K 急性髓系白血病，FLT3突变，靶向治疗<br>Acute Myeloid Leukemia
%K FLT3 Mutation
%K Targeted Therapy
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=65742